Page 76 - GTM-1-2

Global Translational Medicine

REVIEW ARTICLE
Succinate metabolism in cardiovascular diseases

1
Wenxin Shan , Hongtu Cui , Yangkai Xu , Jing Xue , and Lemin Zheng *
1,3
3
2
1
1 The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic
Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education,
NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key
Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University,
Beijing 100 191, China
2 Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; NHC
Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Key Laboratory of
Molecular Cardiovascular Science, Ministry of Education; Beijing Key Laboratory of Cardiovascular
Receptors Research; Research Unit of Medical Science Research Management/Basic and Clinical
Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences; Haihe
Laboratory of Cell Ecosystem, Beijing 100 191, China
3 Beijing Tiantan Hospital, China National Clinical Research Center for Neurological Diseases,
Advanced Innovation Center for Human Brain Protection, The Capital Medical University, Beijing
100 050, China

Abstract

Cardiovascular disease (CVD) refers to a class of diseases related to the heart or
blood vessels that have high global incidence. Succinate is generally considered an
important intermediate product of the tricarboxylic acid cycle. Recent studies have
shown that succinate is related to the pathophysiology of CVD, such as atherosclerosis,
acute aortic dissection, hypertension, myocardial ischemia-reperfusion injury, and
heart failure. It may represent a potential target or biomarker for CVD. It has been
demonstrated that succinate not only participates in various energy metabolic
*Corresponding author: pathways but also plays an important role in various pathophysiological activities as
Lemin Zheng a signaling molecule. Given the significance of metabolism in CVD, it is important to
(zhengl@bjmu.edu.cn) focus on the metabolic regulation mechanism of succinate in CVD. This review outlines
Citation: Shan W, Cui H, Xu Y, the latest evidence pointing to the potential role of succinate in CVD, along with its
et al., 2022, Succinate metabolism mechanisms, and updates the current understanding on the role of succinate in CVD.
in cardiovascular diseases. Global Further studies may focus on identifying succinate, its receptor, and its downstream
Transl Med, 1(2): 160.
https://doi.org/10.36922/gtm.v1i2.160 signaling molecules as new targets for the prevention and treatment of CVD.
Received: July 18, 2022
Accepted: August 30, 2022 Keywords: Cardiovascular diseases; Metabolism; Succinate; Succinate receptor 1
Published Online: September 19,
2022
Copyright: © 2022 Author(s).
This is an Open Access article
distributed under the terms of the 1. Introduction
Creative Commons Attribution
[1]
License, permitting distribution, Cardiovascular disease (CVD) is the leading cause of mortality worldwide . It
and reproduction in any medium, includes atherosclerosis, acute aortic dissection (AAD), hypertension, myocardial
provided the original work is [2,3]
properly cited. ischemia-reperfusion injury (MIRI), heart failure, and metabolic cardiomyopathy .
The progression of the disease cannot be well controlled with medication and surgery.
Publisher’s Note: AccScience
Publishing remains neutral with Therefore, it is particularly important to look for new prevention and treatment targets.
regard to jurisdictional claims in
published maps and institutional Succinate is an important metabolic intermediate of the tricarboxylic acid (TCA)
affiliations. cycle and glutamine metabolism [4,5] . In addition, it acts as a signaling molecule by binding

Volume 1 Issue 2 (2022) 1 https://doi.org/10.36922/gtm.v1i2.160